Stephens & Co. analyst George Sellers reinstates Glaukos (NYSE:GKOS) with a Overweight and announces $69 price target.
What 4 Analyst Ratings Have To Say About First Wave BioPharma
First Wave BioPharma (NASDAQ:FWBI) has observed the following analyst ratings within the last quarter: Bullish Somewhat Bullish Indifferent…